Nanotech Investing Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma
Nanotech Investing Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025
Nanotech Investing NYSE Content Advisory: Pre-Market Update + The AW Playmaker Awards Take the Stage at 11 Wall Street
Nanotech Investing Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer
Nanotech Investing Nuvation Bio Receives Approval from Japan's Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer
Nanotech Investing Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer
